All In Biotech

Drug Trial Radar · NCT07215312

A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin

A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 13, 2025

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Oct 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • LY3938577Drug

    Administered SC

  • DegludecDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Glucose Time in Range Between 70 and 180 mg/dL Inclusive (Non-Inferiority Analysis)Time frame: Baseline through Week 20

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Tucson Clinical Research Institute

    Tucson, Arizona

  • Encompass Clinical Research

    Spring Valley, California

  • University Clinical Investigators, Inc.

    Tustin, California

  • Tampa Bay Medical Research

    Clearwater, Florida

  • Encore Medical Research

    Hollywood, Florida

  • Clinical Research of Central Florida

    Lakeland, Florida

  • Encore Medical Research - Weston

    Weston, Florida

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa

  • Washington University School of Medicine

    St Louis, Missouri

  • Accellacare - Wilmington

    Wilmington, North Carolina

  • AMR Clinical

    Norman, Oklahoma

  • Tribe Clinical Research, LLC

    Greenville, South Carolina

  • Holston Medical Group

    Bristol, Tennessee

  • Texas Diabetes & Endocrinology, P.A.

    Austin, Texas

  • Velocity Clinical Research, Dallas

    Dallas, Texas

  • Juno Research

    Houston, Texas

  • Southern Endocrinology Associates

    Mesquite, Texas

  • Consano Clinical Research, LLC

    Shavano Park, Texas

  • Texas Valley Clinical Research

    Weslaco, Texas

  • Chrysalis Clinical Research

    St. George, Utah

  • Cicemo Srl

    Buenos Aires, Argentina

  • CIPREC

    Buenos Aires, Argentina

  • Mautalen Salud e Investigación

    Buenos Aires, Argentina

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Buenos Aires, Argentina

  • Instituto Centenario

    CABA, Argentina

  • Instituto Médico Catamarca IMEC

    Rosario, Argentina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.